Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CNTA | CLUSTER | bearish | 7/10 | Centessa Pharmaceuticals C-suite executives sold over $7.2M in stock within a week, primarily from Chief People Officer | Mar 16, 2026 |
| BBIO | CLUSTER | bearish | 7/10 | BridgeBio Pharma CEO Kumar Neil sold shares worth over $1.6 million in open-market transactions, while Director Hannah V | Mar 16, 2026 |
| IFF | CLUSTER | bullish | 7/10 | CEO J Erik Fyrwald and Director Paul J Fribourg collectively purchased over $2 million in IFF shares in the past week, w | Mar 16, 2026 |
| UTHR | CLUSTER | bearish | 6/10 | Chairperson & CEO Martine Rothblatt conducted a series of derivative exercises and open-market sales over a 5-day period | Mar 16, 2026 |
| NUVL | CLUSTER | neutral | 4/10 | Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 24,993 shares in open-market transactions over two days, real | Mar 16, 2026 |
| CSTL | CLUSTER | bearish | 7/10 | Multiple C-suite executives at Castle Biosciences sold shares in a concentrated 7-day window, including the CEO selling | Mar 16, 2026 |
| SUPN | CLUSTER | neutral | 4/10 | Two insiders at Supernus Pharmaceuticals sold shares in the past week, including a director and an SVP, with total open- | Mar 16, 2026 |
| ZLAB | CLUSTER | neutral | 4/10 | Zai Lab CEO Du Ying exercised stock options and sold a small number of shares in the open market, while a significant nu | Mar 16, 2026 |
| IPSC | CLUSTER | neutral | 3/10 | A cluster of insider share dispositions occurred at Century Therapeutics over the past week, including open-market sales | Mar 16, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | United Therapeutics CEO Martine Rothblatt sold 1,156 shares in two open-market transactions totaling $616,635 over the p | Mar 16, 2026 |
| ADPT | CLUSTER | bearish | 8/10 | Multiple C-suite executives and directors at Adaptive Biotechnologies sold shares in a concentrated 7-day window, includ | Mar 13, 2026 |
| ADPT | CLUSTER | bearish | 7/10 | Adaptive Biotechnologies CEO Chad Robins sold $1.85M in stock, while President Julie Rubinstein exercised options and so | Mar 13, 2026 |
| DNTH | CLUSTER | bearish | 7/10 | Three Dianthus Therapeutics executives, including the CEO and EVP of R&D, exercised stock options and sold shares in the | Mar 13, 2026 |
| XENE | CLUSTER | bearish | 6/10 | Three executive insiders at Xenon Pharmaceuticals (XENE) sold shares worth over $550K in open-market transactions within | Mar 13, 2026 |
| CNTA | CLUSTER | bearish | 6/10 | Centessa Pharmaceuticals insiders executed a significant share disposition cluster within one day, led by the Chief Peop | Mar 13, 2026 |
| ANIP | CLUSTER | bearish | 6/10 | Seven corporate insiders at ANI Pharmaceuticals sold shares in the past week, including five open-market sales totaling | Mar 13, 2026 |
| PTCT | CLUSTER | neutral | 3/10 | PTC Therapeutics CEO Matthew Klein sold $170,600 of stock in an open-market transaction, while Director Stephanie Okey e | Mar 13, 2026 |
| DYN | CLUSTER | neutral | 4/10 | A director at Dyne Therapeutics sold $2.53 million worth of shares in a single open-market transaction, representing a n | Mar 13, 2026 |
| INDV | CLUSTER | neutral | 2/10 | Director Ryan Barbara made two small open-market purchases of INDV stock totaling approximately $1,258 over the past wee | Mar 13, 2026 |
| CSTL | CLUSTER | bearish | 5/10 | Castle Biosciences CEO Derek Maetzold sold a total of 40,489 shares in the past week, generating approximately $1.04 mil | Mar 13, 2026 |
| ONCY | CLUSTER | bullish | 5/10 | Two corporate insiders at Oncolytics Biotech purchased shares in the open market within the past week, including CEO Kel | Mar 13, 2026 |
| KRRO | CLUSTER | bullish | 8/10 | Multiple insiders and institutional investors in Korro Bio (KRRO) collectively purchased over $20 million in open-market | Mar 12, 2026 |
| ZLAB | CLUSTER | neutral | 3/10 | Zai Lab CEO Du Ying exercised stock options to acquire shares and sold a portion of her holdings in the open market, gen | Mar 12, 2026 |
| TRDA | CLUSTER | neutral | 3/10 | Entrada Therapeutics President & COO Nathan J. Dowden sold a total of 15,010 shares in the past week for approximately $ | Mar 11, 2026 |
| COLL | CLUSTER | neutral | 4/10 | EVP & General Counsel Dieter David sold 6,224 shares in an open-market transaction for approximately $228,110. This is p | Mar 11, 2026 |
| AQST | CLUSTER | bearish | 6/10 | Multiple C-suite executives at Aquestive Therapeutics (AQST) sold shares in the open market, with the CFO, COO, and Chie | Mar 11, 2026 |
| ENTX | CLUSTER | neutral | 4/10 | Two Entera Bio directors, Germano Geno J and Ellis Sean, purchased shares in open-market transactions totaling $38.3K ov | Mar 11, 2026 |
| ADPT | CLUSTER | bearish | 6/10 | Adaptive Biotechnologies COO Julie Rubinstein conducted a series of derivative exercises and open-market sales over thre | Mar 10, 2026 |
| SUPN | CLUSTER | neutral | 4/10 | Multiple insiders at Supernus Pharmaceuticals sold shares in the past week, including SVP William Todd and Director Geor | Mar 10, 2026 |
| ANIP | CLUSTER | neutral | 5/10 | Multiple executives at ANI Pharmaceuticals, including the CEO, CFO, and other senior leaders, engaged in tax-related sha | Mar 10, 2026 |